PROCEPT BioRobotics【PRCT】銘柄情報

PROCEPT BioRobotics Corporation (PRCT) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

27.67

( 2.48% )

買値

21.41

売値

34.17

出来高

1,059,465

26.59 日の範囲 27.89

19.35 52 週間の範囲 66.85

時価総額

1.575B

前日終値

27.00

始値

27.04

時刻

300

27.67

(formt)

最終取引時間

財務取引量

US$ 28,835,461

VWAP

27.217

平均取引量 (3 か月)

US$ 1,578,184

発行済株式数

56,918,844

配当利回り

PER

-14.37

1 株当たり利益 (EPS)

-1.83

歳入

322.02M

純利益

-102.47M

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery f... PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. 詳細を表示

セクター

Healthcare

業界

Medical Equipment & Supplies

ウェブサイト

www.procept-biorobotics.com

本社

San Jose, United States

設立

2026

PROCEPT BioRobotics Corporation is listed in the Healthcare sector of the ナスダック市場 with ticker PRCT. The last closing price for PROCEPT BioRobotics was US$27. Over the last year, PROCEPT BioRobotics shares have traded in a share price range of US$ 19.35 to US$ 66.85.

PROCEPT BioRobotics currently has 56,918,844 shares in issue. The market capitalisation of PROCEPT BioRobotics is US$1.57 billion. PROCEPT BioRobotics has a price to earnings ratio (PE ratio) of -14.37.

Form SD - Specialized disclosure report

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two...

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the...

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June

SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.54	1.99041651309	27.13	28.82	25.95	975915	26.98609493	CS
4	2.17	8.50980392157	25.5	29.62	24.48	1498633	26.96392664	CS
12	1.55	5.93415007657	26.12	29.62	21.28	1365109	25.56891808	CS
26	-7.76	-21.9023426475	35.43	38.11	19.35	1465145	27.4950088	CS
52	-33.84	-55.0154446431	61.51	66.85	19.35	1333836	33.74470864	CS
156	-4.54	-14.0950015523	32.21	103.8099	19.35	884986	46.6668042	CS
260	-7.33	-20.9428571429	35	103.8099	15.38	686545	44.67193334	CS